Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes.
BACKGROUND
Tissue factor (TF) and its inhibitor tissue factor pathway inhibitor (TFPI) are the main regulators of the initiation of the coagulation process, important in atherothrombosis. In this study we have investigated the frequency of six known TF and TFPI single nucleotide polymorphisms (SNPs) in CHD patients as compared to healthy individuals. These genotypes and the phenotypes (TF, TFPI free and total antigen) were evaluated with special reference to gender and diabetes in the CHD population.


METHODS
Patients with angiographically verified CHD (n = 1001; 22% women, 20% diabetics), and 204 healthy controls (28% women), were included. The investigated SNPs were: TF -1812C/T and TF -603A/G in the 5'upstream region, TF 5466A/G in intron 2, TFPI -399C/T and TFPI -287T/C in the 5'upstream region and the TFPI -33T/C in intron 7.


RESULTS
No significant differences in frequencies between the CHD population and the controls of any polymorphisms were observed. In the CHD population, the TF 5466 A/G SNP were significantly more frequent in women as compared to men (p < 0.001). The TF-1812C/T and the TF-603A/G SNPs were significantly more frequent in women without type-2 diabetes compared to those with diabetes (p < 0.018, both), and the heterozygous genotypes were associated with significantly lower TF plasma levels compared to the homozygous genotypes (p < 0.02, both).The TFPI-399C/T and the TFPI-33T/C SNPs were associated with lower and higher TFPI total antigen levels, respectively (p < 0.001, both).


CONCLUSIONS
Genetic variations in the TF and TFPI genes seem to be associated with gender and type-2 diabetes, partly affecting their respective phenotypes.
Opstad
Trine B
TB
Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway. trineoa@medisin.uio.no.
Pettersen
Alf Age
AA
Weiss
Thomas
T
Arnesen
Harald
H
Seljeflot
Ingebjørg
I
Thromb Haemost. 1998 Mar;79(3):495-9
9531029
Thromb Haemost. 2000 Aug;84(2):244-9
10959696
Br J Haematol. 1998 Jul;102(2):605-8
9695980
Thromb Haemost. 2001 Oct;86(4):959-72
11686353
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8869-73
2247459
Diabetes Care. 2004 Dec;27(12):2898-904
15562204
J Intern Med. 1997 Jun;241(6):485-92
10497624
Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2667-72
16239598
Semin Vasc Med. 2003 May;3(2):185-92
15199481
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2839-43
2704749
Scand Cardiovasc J. 2004 Dec;38(6):353-6
15804802
J Diabetes Complications. 2001 Jan-Feb;15(1):44-54
11259926
Thromb Haemost. 1995 Jul;74(1):90-3
8578532
Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):862-9
10195910
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):892-8
10712418
J Thromb Haemost. 2005 Apr;3(4):651-8
15842349
J Thromb Haemost. 2007 Mar;5(3):475-82
17204132
Rev Esp Cardiol. 2003 Oct;56(10):1001-9
14563295
Blood Coagul Fibrinolysis. 1992 Aug;3(4):439-49
1420819
Coron Artery Dis. 1999;10(1):23-30
10196684
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2800-6
17008590
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2311-5
10051638
J Clin Endocrinol Metab. 2007 Nov;92(11):4352-8
17785358
Nature. 1989 Apr 6;338(6215):518-20
2927510
J Pathol. 1999 Jun;188(2):180-8
10398162
Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):802-8
8640408
Thromb Res. 2003;111(6):369-72
14698655
Blood Coagul Fibrinolysis. 2001 Jun;12(4):317-23
11460016
Atherosclerosis. 2004 Nov;177(1):189-91
15488883
Thromb Haemost. 2001 Jun;85(6):999-1003
11434709